prostate cancer

Showing 15 posts of 85 posts found.


AZ and MSD impress at ASCO with Lynparza combo data in prostate cancer

June 5, 2018
Research and Development ASCO, AstraZeneca, Cancer, MSD< pharma, Merck, lynparza, prostate cancer

In another major ASCO reveal, AstraZeneca and partner MSD lifted the curtain at the event on new data for its …


Keytruda offers significant hope in subset of prostate cancer

June 4, 2018
Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical, prostate cancer

Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at …


Sun Pharma drug combo scores FDA approval in advanced castration-resistant prostate cancer

May 23, 2018
Research and Development, Sales and Marketing Cancer, Churchill Pharmaceuticals, FDA, Sun Pharma, US, Yonsa, pharma, prostate cancer

Sun Pharma is celebrating with the announcement that its CYP17 inhibitor Yonsa (abiraterone acetate) has been awarded FDA approval in …


May announces £75m prostate cancer boost

April 10, 2018
Manufacturing and Production, Medical Communications Prostate Cancer UK, UK, biotech, drugs, pharma, pharmaceutical, prostate cancer

Prostate cancer has begun to receive more publicity in recent years in the UK, but not for the right reasons. …


Almost 40% of UK prostate cancer cases are diagnosed late, according to report

April 9, 2018
Medical Communications, Research and Development, Sales and Marketing Cancer, UK, pharma, prostate cancer

A report conducted by charity Orchid has revealed a “worrying trend” in the treatment of prostate cancer, indicating that as …


NHS trials “world-leading” initiative to cut prostate cancer diagnoses to just days

March 5, 2018
Research and Development, Sales and Marketing Cancer, MRI, NHS, pharma, prostate cancer

The NHS has revealed plans to cut the average diagnosis times for prostate cancer from six weeks to less than …


J&J’s apalutamide scores snap FDA approval in castration-resistant prostate cancer subgroup

February 15, 2018
Sales and Marketing Cancer, Erleada, FDA, J&J, JJ, Johsnon & Johnson, apalutamide, pharma, prostate cancer

Johnson & Johnson has announced that its androgen receptor inhibitor apalutamide, now branded as Erleada, has received approval from the …

J&J’s apalutamide shows strength in non-metastatic prostate cancer

February 7, 2018
Research and Development J&J, JJ, Johnson & Johnson, pharma, prostate cancer

Johnson & Johnson unveiled new data at the ASCO Genitourinary Cancer symposium which demonstrated that its androgen receptor antagonist apalutamide …


UK breast cancer mortality falls 10% over five years, overtaken by prostate deaths for first time

February 5, 2018
Research and Development, Sales and Marketing Cancer, Cancer Research UK, breast cancer, pharma, prostate cancer

Breast cancer deaths in the UK have fallen by 10% in the past five years, according to research released by …


17,000 English patients are surviving Stage 4 cancer for two years or more, new data shows

November 8, 2017
Research and Development Cancer, bladder cancer, breast cancer, colon cancer, lung cancer, pharma, prostate cancer

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …


Latest prostate cancer research could provide boost for J&J

June 5, 2017
Research and Development, Sales and Marketing CRUK, Cancer, Johnson & Johnson, prostate cancer

Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third …


Cheap blood test may help tailor prostate cancer treatment

May 4, 2017
Research and Development Blood test, prostate cancer

A blood test that costs less than £50 to perform could prevent men from undergoing treatment with two drugs that …


Clinical trial shows yoga negates side-effects of prostate cancer treatment

April 7, 2017
Medical Communications prostate cancer, prostate treatment, yoga

Men who are treated for prostate cancer display side-effects of treatment by radiation that can often seriously disrupt their personal …


Combination immunotherapy shows promise in castration-resistant prostate cancer

March 13, 2017
Research and Development, Sales and Marketing prostate cancer

Researchers at the University of Texas MD Anderson Cancer Center have found that castration-resistant prostate cancer responds well to a …

Latest content